Büchner T, Hiddemann W, Wörmann B, Rottmann R, Maschmeyer G, Ludwig W D, Zühlsdorf M, Buntkirchen K, Sander A, Aswald J
Department of Internal Medicine, University of Münster, Germany.
Leuk Lymphoma. 1993;11 Suppl 2:21-4. doi: 10.3109/10428199309064257.
After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16-75 (median 50) years was 75% in GM-CSF patients and 84% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and a significantly superior remission duration as of this update two-and-a-half years after the study started. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML.
在第一项研究表明化疗后使用粒细胞巨噬细胞集落刺激因子（GM-CSF）可有效加速高危急性髓系白血病（AML）患者的中性粒细胞恢复并降低早期死亡率之后，开展了第二项研究，在新诊断的AML患者最初的5个化疗疗程中，于化疗前应用GM-CSF并持续至中性粒细胞恢复。16至75岁（中位年龄50岁）患者中，GM-CSF组的完全缓解（CR）率为75%，对照组为84%。GM-CSF组显示出快速清除原始细胞更频繁、持续性白血病更少的趋势，并且在研究开始两年半后的此次更新中，缓解期明显更长。该研究稍后应会表明GM-CSF多疗程启动和长期给药是否会提高AML患者的治愈率。
